Trial Profile
A study evaluating platelet reactivity and platelet thrombin receptor expression in dabigatran treated patients with atrial fibrillation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2017
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Embolism and thrombosis
- Focus Pharmacodynamics
- 16 Jan 2017 New trial record
- 19 Dec 2016 Results published in the Journal of Thrombosis and Haemostasis